Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.81 |
| ▸ | HPGD | P15428 | 4/20 | 0.81 |
| ▸ | NPC1 | O15118 | 3/20 | 0.77 |
| ▸ | RAB9A | P51151 | 3/20 | 0.77 |
| ▸ | BCHE | P06276 | 1/20 | 0.76 |
| ▸ | ACHE | P22303 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2752798 | 0.99 | LMNA (0.82) | LMNAHPGDNPC1RAB9ABCHE | |
| SCHEMBL17656857 | 0.83 | LMNA (0.90) | LMNAHPGDNPC1RAB9AKMT2A | |
| SCHEMBL2751080 | 0.83 | KMT2A (0.97) | LMNAHPGDNPC1RAB9ABCHE | |
| SCHEMBL10144685 | 0.82 | HPGD (0.74) | LMNAHPGDNPC1RAB9ABCHE | |
| SCHEMBL3456287 | 0.82 | KMT2A (0.73) | LMNAHPGDNPC1RAB9AL3MBTL1 | |
| SCHEMBL3455549 | 0.81 | LMNA (0.97) | LMNAHPGDNPC1RAB9ABCHE | |
| SCHEMBL19538657 | 0.80 | KMT2A (0.72) | LMNAHPGDNPC1RAB9AL3MBTL1 | |
| SCHEMBL18715504 | 0.80 | NPC1 (0.88) | LMNAHPGDNPC1RAB9AKMT2A | |
| SCHEMBL16083145 | 0.80 | NPC1 (0.88) | LMNAHPGDNPC1RAB9AKMT2A | |
| SCHEMBL2751507 | 0.78 | CYP1A2 (0.74) | LMNAHPGDNPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | LMNA 4109/4885HPGD 989/4885NPC1 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.